The Anti-CRTAM Chimeric Recombinant Rabbit Monoclonal Antibody (HDAB0314) is a cutting-edge tool for researchers studying CRTAM, a cell surface protein involved in immune regulation and T cell activation. This antibody, developed using advanced recombinant technology and chimeric rabbit monoclonal design, offers high specificity and sensitivity for detecting CRTAM in human samples.With its ability to bind specifically to the CRTAM protein, this antibody enables precise detection and analysis in a variety of cell types, making it ideal for use in immunology and cancer research studies. By targeting CRTAM, researchers can gain valuable insights into immune response modulation and potential therapeutic strategies for diseases like cancer and autoimmune disorders.
The Anti-CRTAM Chimeric Recombinant Rabbit Monoclonal Antibody (HDAB0314) provides a reliable tool for investigating the role of CRTAM in immune regulation and T cell function, offering new avenues for understanding and manipulating immune responses in various disease states. This innovative antibody is a valuable asset for researchers seeking to advance knowledge and develop targeted therapies in the field of immunology.
SKU:
HDAB0314
Size:
100 µg
Clonality:
Monoclonal
Clone:
DMC489
Synonyms:
CD355
Applications:
Flow Cyt
Recommended Dilution:
Flow Cyt 1:100
Host Species:
Rabbit
Isotype:
Rabbit/Human Fc chimeric IgG1
Reactivity:
Human
Purification Method:
Purified from cell culture supernatant by affinity chromatography
Formulation:
Powder
Buffer:
1XPBS
Storage:
Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing).Lyophilized antibodies are shipped at ambient temperature.
Usage:
Research use only
Background:
The CRTAM gene is upregulated in CD4 (see MIM 186940)-positive and CD8 (see CD8A; MIM 186910)-positive T cells and encodes a type I transmembrane protein with V and C1-like Ig domains (Yeh et al., 2008 [PubMed 18329370]).[supplied by OMIM, Feb 2009]